Mr Yang Chen
Mayo Clinic, Rochester (United States of America)
Cardioprotective effects of a novel designer C-type natriuretic peptide-based therapeutic, C53 , for the prevention of post-myocardial infarction heart failure
Event: ESC Congress 2018
Topic: Pharmacotherapy
Session: Targeting reverse remodelling in heart failure
ESC 365 is supported by
